[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345321-105":59,"doc-detail-345321-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","birc5-promoter-driven-nanodrugs-suppress-birc5-positive-cancers-independent-of-abcb1-status-and-ido1-expression-original-research","BIRC5 Promoter-Driven Nanodrugs Suppress BIRC5-Positive Cancers Independent of ABCB1 Status and IDO1 Expression - Original Research","","BIRC5 (survivin) is overexpressed in many tumors and linked to drug resistance, proliferation, and metastasis, while being largely absent in normal differentiated tissues, making it a selective therapeutic target. Two nanodrug formulations were developed using poly-L-lysine–modified NH2-Fe3O4 magnetite nanoparticles for targeting BIRC5-positive cancer cells. Plasmids driven by the BIRC5 promoter encoded antisense BIRC5 mRNA or a dominant-negative survivin protein. In vitro and in vivo zebrafish xenograft testing showed robust anticancer activity across multiple BIRC5-positive lines, unaffected by ABCB1-mediated resistance or IDO1-related insensitivity. Uptake involved clathrin-dependent endocytosis and improved performance after Herceptin conjugation, including in clathrin-deficient SK-BR-3 cells.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/birc5-promoter-driven-nanodrugs-suppress-birc5-positive-cancers-independent-of-abcb1-status-and-ido1-expression-original-research/345321/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/birc5-promoter-driven-nanodrugs-suppress-birc5-positive-cancers-independent-of-abcb1-status-and-ido1-expression-original-research/345321.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-22","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the therapeutic target in this study and why is it selective?","Question",{"text":112,"@type":113},"The target is BIRC5 (survivin). It is broadly overexpressed in tumors but largely undetectable in normal differentiated tissues, supporting selective anticancer targeting.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the nanodrugs designed to suppress BIRC5-positive cancers?",{"text":117,"@type":113},"The study used poly-L-lysine–modified NH2-Fe3O4 magnetite nanoparticles to deliver plasmids driven by the BIRC5 promoter, encoding either antisense BIRC5 mRNA or a dominant-negative BIRC5 protein.",{"name":119,"@type":110,"acceptedAnswer":120},"Does the treatment work independently of ABCB1 or IDO1-related resistance?",{"text":121,"@type":113},"Yes. Anticancer activity was preserved across cancer types and was independent of ABCB1-mediated drug resistance, and it was not affected by IDO1 expression, which is associated with poor immune therapy responses.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345321,1790795967,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","International Journal of Nanomedicine  \n Open Access Full Text Article  \nORIGINAL RESEARCH  \nBIRC5 Promoter-Driven Nanodrugs Suppress BIRC5-Positive Cancers Independent of ABCB1 Status and IDO1 Expression  \nYung-Chieh Chang 1 , 2 , Wei-Lun Huang 3 ,4 , Wu-Chou Su 3 , 5 , Euphemia Leung 6 , Fong-Yu Cheng 7 , Chun Hei Antonio Cheung 8 , 9  \n1TMU Research Center of Cancer Translational Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; 2National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan; 3Center of Applied Nanomedicine, National Cheng Kung University, Tainan, Taiwan; 4Department of Medical Laboratory Science and Biotechnology, National Cheng Kung University, Tainan, Taiwan; 5Department of Oncology, College of Medicine and Hospital, National Cheng Kung University, Tainan, Taiwan; 6Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Grafton, Auckland, New Zealand; 7Department of Chemistry, College of Natural Science and Engineering, Chinese Culture University, Taipei, Taiwan; 8Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan; 9Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan  \nCorrespondence: Chun Hei Antonio Cheung, Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, Email [acheung@mail.ncku.edu.tw](acheung@mail.ncku.edu.tw); Fong-Yu Cheng, Department of Chemistry, College of Natural Science and Engineering, Chinese Culture University, Taipei, Taiwan, [Email ZFY3@ulive.pccu.edu.tw](Email ZFY3@ulive.pccu.edu.tw)  \n\n| Introduction: BIRC5 (survivin), an inhibitor of apoptosis protein, is overexpressed in most tumors and is associated with drug resistance, proliferation, and metastasis, while being largely undetectable in normal differentiated tissues. This unique expression pattern makes BIRC5 an exceptionally selective therapeutic target, offering the potential to maximize anticancer efficacy while minimizing systemic toxicity to healthy tissues. However, few BIRC5-targeted agents have advanced to late-stage clinical trials. Methods: We developed two nanodrug formulations using poly-L-lysine–modified NH2-Fe3O4 magnetite nanoparticles (PL-MNPs) for selective targeting of BIRC5-positive cancer cells. We further evaluated their anti-cancer efficacy in vitro and in vivo (zebrafish xenograft model), using cancer cell models that expressed BIRC5 and exhibited ABCB1-mediated drug resistance and IDO1-induced immune therapy insensitivity.\u003Cbr>Results: The PL-MNPs delivered plasmids driven by the BIRC5 promoter (pBIRC5) encoding either antisense BIRC5 mRNA (AsBIRC5) or a dominant-negative BIRC5 protein (dN-BIRC5), for tumor-specific BIRC5 inhibition. These nanodrugs demonstrated robust in vitro and in vivo anti-cancer activity in multiple BIRC5-positive cell lines (MIA PaCa-2, NTUB1, NTU0.017, SK-OV-3, KB, and KB-TAX50) . The activity was preserved across cancer types and independent of ABCB1-mediated drug resistance, while maintaining cancer cell specificity, and was not affected by IDO1 expression, a factor associated with poor responses to immune therapy. PL-MNP uptake was partially mediated by clathrin-dependent endocytosis, with acidic intracellular environments facilitating efficient plasmid release. Conjugation of nanoparticles with Herceptin® (trastuzumab) significantly increased cellular uptake and anticancer activity, especially in clathrin-deficient SK-BR-3 cells that overexpress ERBB2 .\u003Cbr>Conclusion: These findings establish that the easily synthesized PL-MNP-pBIRC5/As-BIRC5 and PL-MNP-pBIRC5/dN-BIRC5 nanodrugs have strong potential to overcome BIRC5- and ABCB1-related drug resistance, representing a broadly applicable strategy against various malignancies. While the size of our nanodrug (~400 nm in hydrodynamic diameter) is compatible with reported effective nanoparticle","cbCaiduW5eHnHLUj","https://ap.wps.com/l/cbCaiduW5eHnHLUj","pdf",14687565,27,"English","# Introduction\n## Methods\n## Results\n## Conclusion\n# Keywords","[{\"question\":\"What is the therapeutic target in this study and why is it selective?\",\"answer\":\"The target is BIRC5 (survivin). It is broadly overexpressed in tumors but largely undetectable in normal differentiated tissues, supporting selective anticancer targeting.\"},{\"question\":\"How were the nanodrugs designed to suppress BIRC5-positive cancers?\",\"answer\":\"The study used poly-L-lysine–modified NH2-Fe3O4 magnetite nanoparticles to deliver plasmids driven by the BIRC5 promoter, encoding either antisense BIRC5 mRNA or a dominant-negative BIRC5 protein.\"},{\"question\":\"Does the treatment work independently of ABCB1 or IDO1-related resistance?\",\"answer\":\"Yes. Anticancer activity was preserved across cancer types and was independent of ABCB1-mediated drug resistance, and it was not affected by IDO1 expression, which is associated with poor immune therapy responses.\"}]","BIRC5 Promoter-Driven Nanodrugs Suppress BIRC5-Positive Cancers Independent of ABCB1 Status and IDO1 Expression - Original Research | PDF",1790057282,68,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da8c7a85b3c0f135b8031adb16a7e3be.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/67ad4b525d007457784a5012105ca01e.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba1d01705c30d0cd968637722c7b8c4b.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e37e998f1ec0b0832c35957b454584e.webp",980,1268]